Avadel Pharmaceuticals PLC AVDL
We take great care to ensure that the data presented and summarized in this overview for AVADEL PHARMACEUTICALS PLC is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding AVDL
View all-
Knoll Capital Management, LLC Miami, FL600KShares$6.95 Million3.88% of portfolio
-
Knott David M Jr Syosset, NY332KShares$3.85 Million1.53% of portfolio
-
Schulhoff & CO Inc137KShares$1.59 Million0.81% of portfolio
-
1620 Investment Advisors, Inc. Plymouth, MA1KShares$11,5900.01% of portfolio
-
American Portfolios Advisors Holbrook, NY500Shares$5,7950.0% of portfolio
-
American Research & Management Co.100Shares$1,1590.0% of portfolio
-
Exane Derivatives33Shares$3820.0% of portfolio
-
Huntington National Bank Columbus, OH1Shares$110.0% of portfolio
Latest Institutional Activity in AVDL
Top Purchases
Top Sells
About AVDL
Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is FT218, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness and cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals plc in January 2017. Avadel Pharmaceuticals plc was incorporated in 2015 and is headquartered in Dublin, Ireland.
Insider Transactions at AVDL
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jul 30
2024
|
Naseem Amin Director |
BUY
Grant, award, or other acquisition
|
Direct |
11,000
+50.0%
|
-
|
|
Jul 30
2024
|
Eric J Ende Director |
BUY
Grant, award, or other acquisition
|
Direct |
11,000
+5.79%
|
-
|
|
Jul 30
2024
|
Peter J. Thornton Director |
BUY
Grant, award, or other acquisition
|
Direct |
11,000
+10.47%
|
-
|
|
Jul 30
2024
|
Linda Palczuk Director |
BUY
Grant, award, or other acquisition
|
Direct |
11,000
+14.78%
|
-
|
|
Jul 30
2024
|
Geoffrey Michael Glass Director |
BUY
Grant, award, or other acquisition
|
Direct |
11,000
+50.0%
|
-
|
|
Jul 30
2024
|
Mark Anthony Mc Camish Director |
BUY
Grant, award, or other acquisition
|
Direct |
11,000
+50.0%
|
-
|
|
Jan 16
2024
|
Thomas S Mchugh Chief Financial Officer |
BUY
Open market or private purchase
|
Direct |
2,000
+2.42%
|
$28,000
$14.5 P/Share
|
|
Dec 28
2023
|
Mark Anthony Mc Camish Director |
SELL
Open market or private sale
|
Indirect |
75,000
-52.81%
|
$1,050,000
$14.53 P/Share
|
|
Aug 14
2023
|
Thomas S Mchugh Chief Financial Officer |
BUY
Open market or private purchase
|
Direct |
2,000
+2.48%
|
$28,000
$14.45 P/Share
|
|
Aug 11
2023
|
Mark Anthony Mc Camish Director |
SELL
Open market or private sale
|
Indirect |
28,975
-16.94%
|
$405,650
$14.93 P/Share
|
|
Aug 10
2023
|
Geoffrey Michael Glass Director |
BUY
Open market or private purchase
|
Indirect |
14,000
+19.18%
|
$182,000
$13.4 P/Share
|
|
Aug 10
2023
|
Gregory J Divis Chief Executive Officer |
BUY
Open market or private purchase
|
Direct |
10,000
+5.91%
|
$130,000
$13.2 P/Share
|
|
May 18
2023
|
Eric J Ende Director |
BUY
Open market or private purchase
|
Direct |
13,000
+7.19%
|
$169,000
$13.93 P/Share
|
|
May 09
2023
|
Linda Palczuk Director |
BUY
Open market or private purchase
|
Direct |
2,500
+4.55%
|
$35,000
$14.76 P/Share
|
|
Dec 23
2022
|
Linda Palczuk Director |
BUY
Open market or private purchase
|
Direct |
2,000
+3.85%
|
$14,000
$7.2 P/Share
|
|
Nov 29
2022
|
Thomas S Mchugh Chief Financial Officer |
BUY
Open market or private purchase
|
Direct |
5,000
+6.14%
|
$35,000
$7.8 P/Share
|
|
Nov 22
2022
|
Eric J Ende Director |
BUY
Open market or private purchase
|
Direct |
20,000
+11.44%
|
$140,000
$7.8 P/Share
|
|
Jun 01
2022
|
Geoffrey Michael Glass Director |
BUY
Open market or private purchase
|
Indirect |
45,000
+50.0%
|
$90,000
$2.14 P/Share
|
|
Jun 01
2022
|
Eric J Ende Director |
BUY
Open market or private purchase
|
Direct |
20,000
+12.91%
|
$40,000
$2.27 P/Share
|
|
May 31
2022
|
Eric J Ende Director |
BUY
Open market or private purchase
|
Direct |
15,000
+11.55%
|
$30,000
$2.16 P/Share
|
Last 12 Months Summary
| Grant, award, or other acquisition | 66K shares |
|---|---|
| Open market or private purchase | 2K shares |
| Open market or private sale | 75K shares |
|---|